Skip to content

Author

Liang Dong

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients

Allergic bronchopulmonary aspergillosis (ABPA) is a severe type 2 inflammatory airway disease caused by hypersensitivity to Aspergillus fumigatus . Although omalizumab has been used as an adjunctive therapy for ABPA, longitudinal changes in type 2 inflammatory and Aspergillus -specific biomarkers during treat...

Pei-Ze Liu, Meng-Wei Wu, Xu Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.